Trinity Biotech PLC
NASDAQ:TRIB

Watchlist Manager
Trinity Biotech PLC Logo
Trinity Biotech PLC
NASDAQ:TRIB
Watchlist
Price: 1.2 USD 9.09% Market Closed
Market Cap: 23m USD

Trinity Biotech PLC
Investor Relations

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The company is headquartered in Bray, Wicklow. The firm's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. The company operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2024
Call Date
Nov 15, 2024
AI Summary
Q3 2024

Revenue Growth: Trinity Biotech delivered Q3 2024 revenue of $15.2 million, up just over 3% year-over-year, driven by strong TrinScreen HIV sales.

Cost Reduction: Operating loss improved to $2.6 million from $4.5 million in Q3 2023, reflecting ongoing cost-cutting and operational efficiency efforts.

Transformation Progress: The company is on track with its transformation plan, consolidating manufacturing, offshoring production, and centralizing corporate services, with most initiatives expected to complete by early 2025.

TrinScreen Outlook: Management reiterated 2024 TrinScreen HIV sales guidance of approximately $10 million, expecting around $3 million in Q4.

Margin Trends: Gross margin was 35% for the quarter, impacted by higher TrinScreen sales, but expected to improve as operational changes take effect.

New Growth Drivers: Trinity is investing in a next-generation continuous glucose monitor (CGM) and has acquired innovative prostate cancer and preeclampsia diagnostic technologies.

NASDAQ Compliance: The company has regained compliance with NASDAQ listing requirements, removing a key risk overhang.

Key Financials
Revenue
$15.2 million
Point of Care Revenue
$4.3 million
TrinScreen HIV Sales
$2.4 million
Clinical Laboratory Revenue
$10.8 million
Gross Profit
$5.3 million
Gross Margin
35%
SG&A Expenses
$6.5 million
Operating Loss
$2.6 million
Net Loss
$4.8 million
Adjusted EBITDASO
$1.4 million loss
Loss Per ADS
$0.46
Cash Balance
$2.8 million
Cash Used by Operations
$3.6 million
Investing Cash Outflows
$3.1 million
Financing Cash Inflows
$4.2 million
Aftermarket Offering Net Cash Flow
$7.1 million
Annualized Run Rate Revenue (Guidance)
$75 million by Q2 2025
Annualized Run Rate EBITDASO (Guidance)
$20 million by Q2 2025
Earnings Call Recording
Other Earnings Calls

Management

Mr. John Gillard
President, CEO, Company Secretary & Director
No Bio Available
Mr. Ronan O'Caoimh A.C.A.
Founder, Director & Executive Advisor
No Bio Available
Dr. James Walsh Ph.D.
Executive Director of Business Development & Executive Director
No Bio Available
Ms. Louise Tallon
CFO & Chief Accounting Officer
No Bio Available
Ms. Jacqueline O'Neill
Director of Operations
No Bio Available
Dr. Gary Keating Ph.D.
Chief Technology Officer
No Bio Available
Ms. Eibhlin Kelly
Chief Information Officer
No Bio Available
Mr. Colm Molloy
Group Director of Human Resources & Culture
No Bio Available
Mr. Adrian Donohue
Chief Commercial Officer
No Bio Available

Contacts

Address
WICKLOW
BRAY
Ida Business Park, Bray, Co Wicklow, Ireland
Contacts
+1135312955111.0
www.trinitybiotech.com